Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience

Viral Infections, Non-HIV

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

Open Forum Infect Dis

Rainwater-Lovett K, Redd JT, Stewart MA, Calles NE, Cluff T, Fang M, Panaggio MJ, Lambrou AS, Thornhill JK, Bradburne C, Imbriale S, Freeman JD, Anderson M, Kadlec RP

doi: 10.1093/ofid/ofab398

Viral Infections, Non-HIV

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19

Open Forum Infect Dis

Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, Peltan ID, Spivak ES, Shah M, Sakata T, Wallin A, Stenehjem E, Poulsen G, Bledsoe J

doi: 10.1093/ofid/ofab331

Viral Infections, Non-HIV

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents

J Pediatric Infect Dis Soc

Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Marόn-Alfaro GM, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd EE, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM

doi: 10.1093/jpids/piaa175

Viral Infections, Non-HIV

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China

JAMA Intern Med.

Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, Chen J, Wu Y, Xia S, Ling Y, Zhang Y, Xun J, Zhang R, Xie Y, Jiang S, Zhu T, Lu H, Wen Y, Huang J

doi: 10.1001/jamainternmed.2020.4616.

Viral Infections, Non-HIV

Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study

Clin Infect Dis

Kumar RN, Wu EL, Stosor V, Moore WJ, Achenbach C, Ison MG, Angarone MP

doi: 10.1093/cid/ciab305

Viral Infections, Non-HIV

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

N Engl J Med

Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM, BLAZE-1 Investigators.

doi: 10.1056/NEJMoa2102685

Viral Infections, Non-HIV

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

JAMA

Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM

doi: 10.1001/jama.2021.0202

Viral Infections, Non-HIV

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

N Engl J Med

Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM, BLAZE-1 Investigators.

doi: 10.1056/NEJMoa2029849

Viral Infections, Non-HIV

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Clin Infect Dis.

Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, Ballana E, Alemany A, Riera-Martí N, Pérez CA, Suñer C, Laporte P, Admella P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Casabona J, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, Muntada E, Nadal N, Narejos S, Gil-Ortega AN, Prat N, Puig J, Quiñones C, Reyes-Ureña J, Ramírez-Viaplana F, Ruiz L, Riveira-Muñoz E, Sierra A, Velasco C, Vivanco-Hidalgo RM, Sentís A, G-Beiras C, Clotet B, Vall-Mayans M, BCN PEP-CoV-2 RESEARCH GROUP.

doi: 10.1093/cid/ciaa1009.

Related content

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China

Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial